Physician profile
Halima Ghafoor
NPI 1336354398
$3,487.90
in general payments reported to CMS, 2019-2025
25 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $954 · 2020: $498 · 2021: $376 · 2022: $441 · 2023: $376 · 2024: $492 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,218.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $984.30 | 2019-2025 | Trelegy Ellipta |
| Abbvie INC. | $482.80 | 2022-2025 | |
| Pfizer INC. | $382.50 | 2019-2025 | |
| Amgen INC. | $267.79 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $161.73 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.40 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $114.91 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $105.87 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $100.00 | 2019 | |
| Exact Sciences Corporation | $81.58 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $78.19 | 2019-2020 | |
| Lilly USA, LLC | $76.96 | 2021-2025 | Mounjaro |
| Abbott Laboratories | $63.47 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $62.56 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $59.96 | 2021-2023 | Livalo, Seglentis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $53.18 | 2025 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $49.89 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.99 | 2021-2025 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $36.20 | 2021 | |
| Nestle Healthcare Nutrition INC. | $35.79 | 2021 | |
| Medtronic Vascular, INC. | $27.87 | 2019 | |
| Dexcom, INC. | $21.55 | 2024 | Dexcom G6 Transmitter |
| Shire North American Group INC | $21.37 | 2019 | |
| Radius Health, INC. | $19.63 | 2023 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halima Ghafoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.